Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company is conducting a Phase 1 clinical study titled ‘An Open-Label, Phase 1 Study to Investigate the Comparability of the Pharmacokinetics of Olomorasib (LY3537982) Between Two Capsule Formulations and to Evaluate the Food Effect in Healthy Japanese Participants.’ The study aims to compare how food affects the absorption of Olomorasib in two different capsule forms, highlighting its significance in optimizing drug delivery.
The intervention being tested is Olomorasib, an oral drug, administered in two formulations to assess its pharmacokinetics with and without food intake.
This interventional study is designed as a randomized crossover trial with no masking, focusing on basic science to understand the drug’s behavior in the body.
The study is set to start in September 2025, with primary completion and estimated completion dates yet to be determined. The last update was submitted on August 13, 2025, indicating the study’s preparation phase.
For investors, this study could influence Eli Lilly’s stock performance by potentially enhancing their product pipeline with a new formulation. The study’s progress and outcomes might also impact investor sentiment, especially in the competitive pharmaceutical industry where innovation is key.
The study is ongoing, with further details available on the ClinicalTrials portal.